BETTEN-AID SIMPLE HEARTBURN RELIEF
  • Your heartburn meds are killing you!
    • Top 5 Reasons Never to Take a Proton Pump Inhibitor
    • Heartburn Meds Tied to Higher Diabetes Risk
    • Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID‐19: a meta‐analysis
    • Reflux Drugs Tied to Bone Fractures in Children
    • Heartburn drugs linked to fatal heart and kidney disease, stomach cancer
    • Millions of Canadians using acid-reflux drugs for too long, risking health side-effects
    • Using friendly bacteria to treat Irritable Bowel Syndrome
    • Proton Pump Inhibitors: How to Deprescribe These Nutrient Robbers
    • Pneumonia Risk with PPI Use Continues Past One Year, Researchers Say
    • Acidity and Heartburn Medications May Up Risk Of Pneumonia In The Elderly
    • Babies Given Antibiotics or Antacids May Be More Likely to Have Allergies, Study Finds
    • Study Links Popular Heartburn Drugs to Esophageal Cancer
    • The Purple Pill in the Red Zone
    • PPIs Linked to Pancreatic Cancer, Death
    • Guidelines for Limiting Unnecessary Use of Proton Pump Inhibitors
    • Superbug’ may depend on calcium to multiply
    • Some heartburn drugs linked with higher risk of death
    • Probiotics, Enzymes to Support Gut Health
    • Infants prescribed antacids for reflux have increased risk of bone fractures
    • How reflux drugs could raise fracture risk in babies
    • Heartburn Meds: Do They Do More Harm Than Good?
    • Day after Super Bowl, 16 million stay home on 'Super Sick Day'
    • Heartburn Medication Linked to Increased Risk of First Time Stroke
    • The Use Of Common Drugs For Heartburn Now Linked To Developing Stroke, Study Finds
    • Could common heartburn drugs increase stroke risk?
    • Stomach Flu More Common in PPI Users
    • Proton Pump Inhibitors May Reduce Efficacy of Capecitabine
    • Do This One Easy Thing If You Want Garbage In Your Cells
    • Proton Pump Inhibitor Lawsuits Mount
    • Study: PPI Acid Reflux Drugs Overused in People with GI Bleeds
    • PPI Heartburn Drugs Linked to Brain Problems, Fluid Build Up
    • Should you be taking stomach-acid reducers?
    • Dementia
    • Mental Health >
      • One-third of US adults may unknowingly use medications that can cause depression
      • Stomach acid drugs may cause depression
    • Heart Disease >
      • Giving PPIs and Antibiotics Together May Disrupt Heart Rhythm
      • Study Shows Heartburn Drugs Increase Risk of Cardiovascular Complications
    • Increased Infections >
      • AH-CHOO! THESE MEDS LINKED WITH HIGHER ALLERGY RISK IN KIDS
      • Acid Suppression Drugs Linked to Gastrointestinal Infections
      • PPIs increase risk for hepatic encephalopathy, spontaneous bacterial peritonitis
    • Kidney Failure >
      • ASN: PPIs associated with increased risk of kidney disease
      • Proton Pump Inhibitors May Increase Risk for Kidney Disease
      • Proton Pump Inhibitor Drugs Linked To Silent Kidney Damage
      • Popular OTC Acid Reflux Medicines May Carry Substantial Negative Side Effects, Studies Show
    • Osteoporosis >
      • New Concerns over Suspected Link Between Nexium and Osteoporosis
  • What is Betten-Aid?
    • Tummy Trouble Is On The Rise Among Americans, Gastrointestinal Experts Say
  • Store
  • A new Paradigm in Acid Reflux.
  • Natural vs. Synthetic
  • National group wants cancer warning labels on acid reflux drugs

Proton Pump Inhibitors: How to Deprescribe These Nutrient Robbers

Many medications can cause nutritional deficiencies, and proton pump inhibitors (PPIs) are no different. 

First is magnesium deficiency. Several reports have linked long-term PPI use with an increased risk of hypomagnesemia, especially over a year.1 Results of studies suggest that PPIs inhibit active transport of magnesium in the intestine.1 Severe hypomagnesemia can potentially lead to serious adverse effects including arrhythmias, hypocalcemia, hypokalemia, hypoparathyroidism, muscle spasms, and seizures. Suggested supplementation of magnesium is 250 to 400 mg/day.2

Second is vitamin B12 rated as a moderate depletion. Monitoring of vitamin B12 is recommended, and some people may need a supplement.1Unless PPI use is prolonged (2 years or more) or dietary vitamin intake is low, clinically significant vitamin B12deficiency is unlikely. Furthermore, vitamin B12 deficiency is more likely in individuals taking high doses of PPIs. The good news is that vitamin B12deficiency is expected to diminish after patients discontinue PPI therapy.1

Because gastric acid is needed to release vitamin B12 from protein for absorption, PPIs can reduce the absorption of protein-bound (dietary) vitamin B12.1 Suggested supplementation of vitamin B12 is 25 to 400 μg/day.2

In addition, the Natural Medicines Comprehensive Database rates dibencozide as a moderate depletion.1
 
For details on other depletions induced by PPIs and H2blockers, see the Table.1  

Growing Concern
It is common for PPIs to be continued for prolonged periods and, in some cases, indefinitely. But long-term use of PPIs can lead to adverse effects, drug interactions, misuse or overuse, and prescribing cascades.3

In addition to nutrient depletion, PPIs have been linked to an increased risk of Clostridium difficile and pneumonia infections, kidney damage, and osteoporotic fractures.4

Deprescribing
There are several methods for deprescribing PPIs, including stopping (abrupt discontinuation or tapering), stepping down (ceasing taking medication, followed by H2blocker therapy), and reducing (intermittent PPI use, on-demand PPI use, or lowering the dose).5 Regardless of the approach, the overall goal of deprescribing is to avoid adverse effects, improve or maintain quality of life, and reduce inappropriate medicine use.3,5

Although there have been small studies that have demonstrated successful deprescribing methods, there had been no guidelines to describe the benefits and drawbacks of deprescribing until now.3

Evidence-based guidelines to help clinicians deprescribe PPIs were published in the Canadian Family Physicianjournal in 2017.5 These guidelines used a systematic review of deprescribing trials and examined reviews regarding the harm associated with the continued use of PPIs. The development of these guidelines involved a team comprising a family physician, a gastroenterologist, 3 pharmacists, and 5 nonvoting members.5

The guidelines are designed to help clinicians make decisions about how and when to deprescribe PPIs. They are meant to be used in conjunction with treatment guidelines for gastroesophageal reflux disease (GERD) and peptic ulcer disease, and they take into account a patient’s personal situation and are not meant to dictate decision making, the authors noted.5For the PPI deprescribing algorithm, see the Figure.5

On-demand PPI use is defined as taking a PPI for a period that is sufficient to achieve symptom resolution. Upon symptom resolution, the PPI is to be discontinued until the symptoms recur, in which case, the PPI will again be taken daily until symptoms resolve.5 These recommendations are not for individuals with Barrett esophagus, a history of bleeding GI ulcers, or severe esophagitis (grade C or D, as defined by the Los Angeles Classification for the endoscopic assessment of reflux esophagitis), the authors noted.5

In addition, there is a recently published Cochrane systematic review that may be of value when considering deprescribing PPIs.3

The authors noted that there are several situations in which continued use of PPIs may be needed and listed those in the algorithm. Furthermore, they recommended seeking advice from a gastroenterologist to assess continuing risk factors for GI disease.5

Many of the deprescribing trials included follow-up post deprescribing. Because of this, the investigators recommended establishing a post-deprescribing plan that includes a follow-up after 4 weeks to assess symptom control and after 12 weeks to assess symptoms, the frequency of on-demand use, and other factors, as well as to reassess the need to go back on continuous treatment.5

Anyssa Garza, PharmD, BCMAS, received her doctor of pharmacy degree from The University of Texas at Austin. She is the vice president of Content and Patient Education Programs at Digital Pharmacist and an adjunct assistant professor at The University of Texas at Austin College of Pharmacy. 
 
References
1. Nutrient depletion. Natural Medicines Comprehensive Database website. naturaldatabase.com. Accessed June 12, 2018.
2. Common drug classes, drug-nutrient depletions, & drug-nutrient interactions. Nature Made website. naturemade.com/~/media/Images/NatureMade/PDF/Health%20Care%20Professionals/HCP%20Updates%20042315/Common%20Drug%20Classes%20and%20Nutrient%20Interactions%20Chart%20FNL.ashx. Published 2015. Accessed May 6, 2018.
3. Boghossian TA, Rashid FJ, Thompson W, et al. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Database Syst Rev.2017;3:CD011969. doi: 10.1002/14651858.CD011969.pub2.
4. Yu LY, Sun LN, Zhang XH, et al. A review of the novel application and potential adverse effects of proton pump inhibitors. Adv Ther.2017;34(5):1070-1086. doi: 10.1007/s12325-017-0532-9.
5. Farrell B, Pottie K, Thompson W, et al. Deprescribing proton pump inhibitors: evidence-based clinical practice guideline. Can Fam Physician.2017;63(5):354-364. 
 ​
Picture
​https://www.pharmacytimes.com/publications/issue/2018/july2018/proton-pump-inhibitors-how-to-deprescribe-these-nutrient-robbers-
Powered by Create your own unique website with customizable templates.